Curated News
By: NewsRamp Editorial Staff
March 10, 2026
Oragenics Advances Concussion Treatment with Phase IIa Trial Approval in Australia
TLDR
- Oragenics gains first-mover advantage with its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for concussion, positioning it ahead in the neurosteroid market.
- Oragenics secured Australian ethics approval for a randomized, placebo-controlled Phase IIa trial of ONP-002, enrolling 40 patients to assess safety and tolerability before a U.S. IND application.
- This trial advances a novel intranasal treatment for concussion, potentially improving recovery for millions with traumatic brain injuries and enhancing neurological care worldwide.
- Oragenics is testing a brain-targeted neurosteroid delivered via the nose, a unique approach that could also help treat Parkinson's, Alzheimer's, and anxiety disorders.
Impact - Why it Matters
This development matters because concussion and mild traumatic brain injury affect millions globally, from athletes to accident victims, often leading to long-term cognitive and neurological issues without effective treatments. Oragenics' ONP-002 represents a novel approach using intranasal delivery to target the brain directly, potentially offering faster and more effective relief compared to traditional methods. If successful, it could set a new standard in neurosteroid therapy, reducing recovery times and improving quality of life for patients. Moreover, the company's platform has broader implications for other neurological conditions, suggesting a transformative impact on healthcare. For investors and the medical community, this trial marks a critical step toward addressing a significant unmet need, with potential ripple effects in sports medicine, military health, and general neurology.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company, has achieved a significant milestone by securing final Human Research Ethics Committee approval in Australia to launch its Phase IIa clinical trial for ONP-002, a promising intranasal neurosteroid candidate designed to treat concussion, also known as mild traumatic brain injury (mTBI). With all regulatory hurdles cleared, the company has begun clinical site onboarding at three Australian locations, spearheaded by Bayside Health (Alfred Health), and anticipates dosing the first patient before the end of March. This randomized, placebo-controlled study will enroll 40 patients to assess the safety, tolerability, and feasibility of ONP-002, with data expected by late 2026, paving the way for a future investigational new drug application to support additional U.S. clinical trials. For more details, the full press release is available via the InvestorBrandNetwork.
Oragenics is leveraging its proprietary intranasal delivery technology to develop brain-targeted therapeutics, with ONP-002 positioned as a potential first-in-class treatment for concussion and mTBI. The company's broader platform holds promise for addressing various neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, underscoring its commitment to tackling unmet medical needs in neurological care. Investors and stakeholders can stay updated through the company's newsroom, which is part of the Dynamic Brand Portfolio managed by IBN, a specialized communications platform that enhances press release syndication and corporate outreach. This news highlights Oragenics' strategic progress in advancing innovative therapies that could revolutionize treatment options for brain injuries and related disorders.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Advances Concussion Treatment with Phase IIa Trial Approval in Australia
